Stockscreener 앱 받기
48.86
0.08%
-0.04
시간 외 거래:
48.86
전일 마감가:
$48.90
열려 있는:
$49.25
하루 거래량:
1.06M
Relative Volume:
0.78
시가총액:
$10.55B
수익:
$1.98B
순이익/손실:
$83.59M
주가수익비율:
130.64
EPS:
0.374
순현금흐름:
$502.31M
1주 성능:
-0.67%
1개월 성능:
-5.66%
6개월 성능:
+24.80%
1년 성능:
+5.09%
1일 변동 폭
$48.78
$49.28
1주일 범위
$48.78
$49.96
52주 변동 폭
$37.74
$51.88
Qiagen Nv Stock (QGEN) Company Profile
QGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
48.86 | 10.55B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
488.48 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
206.25 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.72 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
118.30 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.76 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-04 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-10-17 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2024-06-27 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-07 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-09-12 | 개시 | Robert W. Baird | Outperform |
| 2023-05-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-01-18 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-10-14 | 개시 | Redburn | Buy |
| 2021-07-14 | 다운그레이드 | Kepler | Buy → Hold |
| 2021-06-03 | 개시 | Goldman | Neutral |
| 2020-10-06 | 재개 | BofA Securities | Buy |
| 2020-09-28 | 업그레이드 | Kepler | Hold → Buy |
| 2020-08-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-20 | 재개 | JP Morgan | Overweight |
| 2020-08-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-08-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-08-14 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-12-26 | 재개 | BofA/Merrill | Underperform |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-11-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-11-14 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2019-11-14 | 업그레이드 | Kepler | Reduce → Hold |
| 2019-10-17 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | 다운그레이드 | Kepler | Hold → Reduce |
| 2019-10-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-10-08 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
Qiagen Nv 주식(QGEN)의 최신 뉴스
What makes Qiagen N.V. stock price move sharply2025 Stock Rankings & Verified Swing Trading Watchlists - thegnnews.com
QIAGEN NV : Gets a Buy rating from Deutsche Bank - MarketScreener
Qiagen Manager Sells $1.23M in Shares for Asset Allocation - AInvest
QIAGEN Executive Sells Significant Shareholding - TipRanks
Qiagen Executive Sells Significant Shareholding - TipRanks
QIAGEN Manager Sells Shares for Asset Allocation - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
QIAGEN N.V. Announces Managerial Share Sale by Roland Sackers - TipRanks
Qiagen N.V. Reversal Rally May Surprise Bears2025 Stock Rankings & Fast Moving Market Watchlists - metal.it
Upbeat Q2 Results and Raised Outlook Could Be a Game Changer for Qiagen (QGEN) - simplywall.st
Sector Leaders Rotate Capital Into Qiagen N.V.July 2025 Spike Watch & AI Based Buy/Sell Signal Reports - newsyoung.net
Qiagen N.V. shares rise 1.09% intraday as DAX index climbs toward record high. - AInvest
Will Qiagen N.V. Hold Gains Into CloseJuly 2025 Fed Impact & Growth Focused Investment Plans - sundaytimes.kr
Sentiment Turns Positive on Qiagen N.V. — Reversal AheadJuly 2025 Movers & Long-Term Capital Growth Strategies - classian.co.kr
PATENT—Fed. Cir.: Qiagen did not infringe Labcorp's DNA sequencing preparation patents; $4.7M jury verdict reversed - VitalLaw.com
How Investors Are Reacting To Qiagen (QGEN) Return to Profitability and Upgraded 2025 Sales Outlook - simplywall.st
Contradictions Unveiled: Qiagen's 2025Q2 Earnings Call Highlights Divergent Views on Market Performance and Growth - AInvest
Is Qiagen N.V. stock showing strong momentumFree Trend Reversal Signals - newsyoung.net
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - Yahoo Finance
STD Diagnostic Market Forecast and Company Analysis Report 2025-2033 Featuring Siemens, Abbott, MedMira, QIAGEN, Danaher, F. Hoffmann-La Roche, Diasorin, BioMeriuex, Hologic, Bio-Rad Laboratories - GlobeNewswire Inc.
Why Qiagen (QGEN) International Revenue Trends Deserve Your Attention - sharewise.com
Investors Interested In Qiagen N.V.'s (NYSE:QGEN) Earnings - 富途牛牛
Europe Molecular Oncology Diagnostics Market Research Report 2024-2033 | Competitive Analysis of Biocartis Group, bioMerieux, F. Hoffmann-La Roche, QIAGEN - Yahoo Finance
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $49 to $50 - 富途牛牛
Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
Why Qiagen N.V. stock attracts strong analyst attentionMulti-Year Breakout Candidates - sisain.net
QIAGEN Reports Strong Q2 2025 Results, Raises Sales Outlook - The Globe and Mail
UBS Adjusts Price Target on QIAGEN to $50 From $48, Maintains Neutral Rating - MarketScreener
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $50 to $55 - 富途牛牛
UBS Maintains Qiagen NV(QGEN.US) With Hold Rating, Announces Target Price $50 - 富途牛牛
Qiagen N.V. (NYSE:QGEN) Q2 2025 Earnings Call Transcript - Insider Monkey
QIAGEN NV : Jefferies maintains a Buy rating - MarketScreener
Qiagen Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Qiagen N.V. shares rise 1.16% premarket after Deutsche Bank reaffirms Buy rating and Q2 earnings beat expectations. - AInvest
QIAGEN Exceeds Q2 2025 Outlook with 7% Sales Growth and Improved Profitability - AInvest
Transcript : Qiagen N.V., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Qiagen: Better than expected Q2; sales guidance upgraded - MarketScreener
QIAGEN NV : Deutsche Bank reaffirms its Buy rating - MarketScreener
Activist investor Fivespan takes stake in QiagenBloomberg - MSN
Qiagen N.V. shares fall 1.22% premarket despite exceeding Q2 2025 outlook with solid growth. - AInvest
Qiagen NV Reports Strong Q2 Earnings, Surpasses Revenue ExpectationsNews and Statistics - IndexBox
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability - BioSpace
Qiagen: Q2 Earnings Snapshot - The Washington Post
Qiagen (QGEN) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Qiagen NV reports results for the quarter ended June 30Earnings Summary - TradingView
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability | QGEN Stock News - GuruFocus
Qiagen reports Q2 adjusted EPS 62c, consensus 60c - TipRanks
Qiagen reports Q2 2025 net sales $534 million, adjusted EPS $0.6 - MarketScreener
Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk - simplywall.st
What to Expect from Qiagen NV (QGEN) Q2 2025 Earnings - GuruFocus
Can Qiagen N.V. Escape Recent Bear ChannelRisk Managed Trade Playbook Insight - beatles.ru
Qiagen Nv (QGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.02%
0.95%
자본화:
|
볼륨(24시간):